Cellectar Biosciences (CLRB) executive compensation, 2026 proxy

James V. Caruso, President and Chief Executive Officer, was paid $1.1M in 2025, down 65% from $3M the year before.

Filed
May 28, 2026
Annual meeting
July 7, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.1M-65% vs prior year
CEO salary
$676,0002025 base salary
CEO option awards
$210,60030,000 shares
CEO incentive compensation
$169,0002025 incentive-plan compensation
COO total compensation
$766,995Jarrod Longcor
CFO total compensation
$620,355Chad J. Kolean
Caruso bonus target
55%Initial target of base salary

How Caruso was paid

$1.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary64%Option awards20%Non-equity incentive16%

Named executive officers

ExecutiveTotal
James V. CarusoPresident and Chief Executive Officer$1,055,600
Jarrod LongcorChief Operating Officer$766,995
Chad J. KoleanChief Financial Officer$620,355

What changed and why

  • $1.1M$1,055,600 was CEO total compensation in 2025, down from $3,042,750 in 2024.
  • $676K$676,000 was the CEO’s 2025 salary, compared with $650,000 in 2024.
  • $211K$210,600 was the CEO’s 2025 option-award value for 30,000 shares.
  • $169K$169,000 was the CEO’s 2025 incentive-plan compensation.
  • $767K$766,995 was COO Jarrod Longcor’s 2025 total compensation.
  • $620K$620,355 was CFO Chad J. Kolean’s 2025 total compensation.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.